Репозиторий OAI—PMH
Репозиторий Российская Офтальмология Онлайн по протоколу OAI-PMH
Конференции
Офтальмологические конференции и симпозиумы
Видео
Видео докладов
| Реферат RUS | Реферат ENG | Литература | Полный текст |
| УДК: | 617.736 DOI: https://doi.org/10.25276/2410-1257-2023-3-11-16 |
Бикбов М.М., Гильманшин Т.Р., Кудоярова К.И.
К вопросу о резистентности диабетического макулярного отека
1. Бикбов М.М., Гильманшин Т.Р., Зайнуллин Р.М., Кудоярова К.И. К вопросу об эпидемиологии сахарного диабета и ди-абетической ретинопатии в Республике Башкортостан. Acta Biomedica Scientifica. 2019;4(4): 66–69. [Bikbov MM, Gil'manshin TR, Zainullin RM, Kudoyarova KI. Epidemiology of diabetic retinopathy in the republic of Bashkortostan. Acta Biomedica Scientifica. 2019;4(4): 66–69. (In Russ.)] doi: 10.29413/ABS.2019-4.4.9
2. Castro-Navarro V, Cervera-Taulet E, Navarro-Palop C, et al. Intravitreal dexamethasone implant Ozurdex® in naive and refractory patients with different subtypes of diabetic macular edema. BMC Ophthalmol. 2019;19(1): 15. doi: 10.1186/s12886-018-1022-9
3. Choi MY. Characteristics of diabetic macular edema patients refractory to anti-VEGF treatments and a dexamethasone implant. PloS One. 2019;14(9): e0222364. doi: 10.1371/journal.pone.0222364
4. Санторо Э.Ю. Опыт применения афлиберцепта в лечении ди-абетического макулярного отека по стандартному протоколу в реальной клинической практике. Российский офтальмоло-гический журнал. 2018;11(4): 80–85. [Santoro EYu. Experiences of using aflibercept in diabetic macular edema treatment: data from routine clinical practice. Russian ophthalmological journal. 2018;11(4): 80–85 (In Russ.)] doi: 10.21516/2072-0076-2018-11-4-80-85
5. Forrester JV, Kuffova L, Delibegovic M. The Role of Inflammation in Diabetic Retinopathy. Front Immunol. 2020;6(11): 583–687. doi: 10.3389/fimmu.2020.583687
6. Mesquida M, Drawnel F, Fauser S. The role of inflammation in diabetic eye disease. Semin Immunopathol. 2019;41(4): 427–445. doi: 10.1007/s00281-019-00750-7
7. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F. Clinical guidelines of the European Society of Retinologists (EURETINA) for the treatment of diabetic macular edema. Ophthalmologica. 2017;25.
8. White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, Davis MD. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010;59: 1244–1253. doi: 10.2337/db09-1216
9. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep. 2012;12: 364–375. doi: 10.1007/s11892-012-0281-8
10. Busch C, Zur D, Fraser-Bell S, Lains I, at al. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetologica. 2018;55: 789–796. doi: 10.1007/s00592-018-1151-x
11. Каменских Т.Г., Батищева Ю.С., Колбенев И.О. и др. Опыт ан-тиангиогенной и кортикостероидной терапии диабетиче-ского макулярного отека. Саратовский научно-медицинский журнал. 2017;13(2): 383–388. [Kamenskikh TG, Batishcheva YuS, Kolbenev IO, et al. Experience of antiangiogenic and corticosteroid therapy of a diabetic macular edema. Saratovskii nauchno-meditsinskii zhurnal. 2017;13(2): 383–388. (In Russ.)]
12. Martinez AH, Delgado EP, Silva G, at al. Early versus late switch: How long should we extend the anti-vascular endothelial growth factor therapy in unresponsive diabetic macular edema patients? European Journal of Ophthalmology. 2020;30(5): 1091–1098. doi: 10.1177/1120672119848257
13. Gonzalez VH, Campbell J, Holekamp NM, et al. Early and Longterm Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. American. J Ophthalmology. 2016;172: 72–79. doi.org/10.1016/j.ajo.2016.09.012
14. Chawan-Saad J, Wu M, Wu A, Wu L. Corticosteroids for Diabetic Macular Edema. Taiwan. J Ophthalmol. 2019;9(4): 233–242. doi: 10.4103/tjo.tjo_68_19
15. Elbay A, Kirik F, Ekinci C, Koytak A. Regression of Serous Macular Detachment After Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema. J Ocul Pharmacol Ther. 2019;24. doi: 10.1089/jop.2019.0028
16. Chang-Lin J, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52: 80–86. doi: 10.1167/iovs.10-5285
17. Kodjikian L. International, Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies. BioMed. 2018;8289253: 16. doi: 10.1155/2018/8289253
18. Pacella E, Vestri AR, Muscella R, et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex) in patients with persistent diabetic macular edema. Clin Ophthalmol. 2013;7: 1423–1428. doi: 10.2147/OPTH.S48364
19. Bikbov MM, Gilmanshin TR, Zainullin RM, et al. Macular pigment optical density and its determinants in a russian population: the ural eye and medical study. Acta Ophthalmologica. 2022;100(8): e1691–e1700. doi: 10.1111/aos.15131
20. Garcia-Layana A, Figueroa MS, Arias L, et al. Clinical DecisionMaking when Treating Diabetic Macular Edema Patients with Dexamethasone Intravitreal Implants. Ophthalmologica. 2018;240(2): 61–72. doi: 10.1159/000486800
21. Iglicki M, Busch C, Zur D, et al. Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes. Retina. 2019;39(1): 44–51. doi: 10.1097/IAE.0000000000002196
Страница источника: 11
Каталог
Продукции
Организации
Офтальмологические клиники, производители и поставщики оборудования
Издания
Периодические издания
Партнеры
Проекта Российская Офтальмология Онлайн
